News

01.04.2020
New IHC antibodies for PRAME and pan-TRK (NTRK)
New IHC antibodies for PRAME and pan-TRK (NTRK)

medac Diagnostics is extending ist product portfolio in the I H C range with e.g. antibodies for PRAME and NTRK (pan-TRK).
   
PRAME
   
Clone: RBT-PRAME; species: monoclonal rabbit; RUO status; CE-IVD from autumn 2020
   
In general, normal, benign tissue does not express PRAME, with the exception of testicles, ovaries, placenta, adrenal glands and endometrium. Because of this expression profile, PRAME is considered part of the cancer/testis antigens (CTA) group. A significant overexpression of PRAME (preferentially expressed antigen in melanoma) was detected in the primary tumours (83.2%) and metastases (87%) of melanoma. PRAME is expressed to a similar extent in different melanoma subtypes, with the exception of desmoplastic melanoma where the expression rate is significantly lower at 35%.
   
NTRK (pan-TRK)
   
Clone: RBT-TRK; species: monoclonal rabbit; RUO status; CE-IVD from autumn 2020
   
The term NTRK (neurotrophic tyrosine receptor kinase) includes three genes (NTRK1/NTRK2/NTRK3) which encode the tropomyosin receptor kinases Trk A, Trk B and Trk C. An NTRK gene can become an oncogene when it fuses with another gene (e.g. ETV6, EML4, TPM3) and is activated permanently as a result. NTRK gene fusions are thus considered oncogenic drivers and can trigger different signalling pathways that encourage the growth of tumours.
   
You can find more information on both antibodies on our

News archive